EUROAPI SASU(EPA:EAPI) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to EAPI. EAPI was compared to 51 industry peers in the Pharmaceuticals industry. The financial health of EAPI is average, but there are quite some concerns on its profitability. EAPI is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

EAPI had negative earnings in the past year.

In the past year EAPI had a positive cash flow from operations.

In the past 5 years EAPI always reported negative net income.

Each year in the past 5 years EAPI had a positive operating cash flow.

1.2 Ratios

With a Return On Assets value of -8.77%, EAPI is not doing good in the industry: 68.63% of the companies in the same industry are doing better.

The Return On Equity of EAPI (-13.28%) is worse than 68.63% of its industry peers.

		Industry Rank	Sector Rank
ROA	-8.77%
ROE	-13.28%
ROIC	N/A

ROA(3y)-7.13%

ROA(5y)-4.46%

ROE(3y)-11.69%

ROE(5y)-7.3%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

EAPI has a worse Gross Margin (15.49%) than 82.35% of its industry peers.

In the last couple of years the Gross Margin of EAPI has grown nicely.

EAPI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	15.49%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y8.23%

GM growth 5Y10.12%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EAPI does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, EAPI has more shares outstanding

Compared to 5 years ago, EAPI has more shares outstanding

EAPI has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 1.97 indicates that EAPI is not a great score, but indicates only limited risk for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 1.97, EAPI is in line with its industry, outperforming 45.10% of the companies in the same industry.

The Debt to FCF ratio of EAPI is 4.63, which is a neutral value as it means it would take EAPI, 4.63 years of fcf income to pay off all of its debts.

Looking at the Debt to FCF ratio, with a value of 4.63, EAPI is in line with its industry, outperforming 56.86% of the companies in the same industry.

A Debt/Equity ratio of 0.06 indicates that EAPI is not too dependend on debt financing.

The Debt to Equity ratio of EAPI (0.06) is better than 84.31% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.06
Debt/FCF	4.63
Altman-Z	1.97

ROIC/WACCN/A

WACC7.43%

2.3 Liquidity

A Current Ratio of 2.53 indicates that EAPI has no problem at all paying its short term obligations.

The Current ratio of EAPI (2.53) is better than 86.27% of its industry peers.

EAPI has a Quick Ratio of 2.53. This is a bad value and indicates that EAPI is not financially healthy enough and could expect problems in meeting its short term obligations.

EAPI has a Quick ratio of 0.93. This is comparable to the rest of the industry: EAPI outperforms 43.14% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.53
Quick Ratio	0.93

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

EAPI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.38%, which is quite impressive.

EAPI shows a decrease in Revenue. In the last year, the revenue decreased by -9.79%.

EAPI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.07% yearly.

EPS 1Y (TTM)31.38%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%62.14%

Revenue 1Y (TTM)-9.79%

Revenue growth 3Y0.98%

Revenue growth 5Y0.07%

Sales Q2Q%-10.01%

3.2 Future

The Earnings Per Share is expected to grow by 26.56% on average over the next years. This is a very strong growth

EAPI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.07% yearly.

EPS Next Y58.04%

EPS Next 2Y42.16%

EPS Next 3Y35.66%

EPS Next 5Y26.56%

Revenue Next Year-0.96%

Revenue Next 2Y-2.87%

Revenue Next 3Y-0.73%

Revenue Next 5Y0.07%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EAPI. In the last year negative earnings were reported.

Also next year EAPI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

EAPI's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. EAPI is cheaper than 100.00% of the companies in the same industry.

Based on the Price/Free Cash Flow ratio, EAPI is valued a bit cheaper than the industry average as 68.63% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	17.62
EV/EBITDA	3.04

4.3 Compensation for Growth

EAPI's earnings are expected to grow with 35.66% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y42.16%

EPS Next 3Y35.66%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for EAPI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EUROAPI SASU

EPA:EAPI (5/14/2025, 7:00:00 PM)

2.746

+0.01 (+0.22%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)03-03 2025-03-03/amc

Earnings (Next)07-29 2025-07-29

Inst Owners48.55%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap262.49M

Analysts43.33

Price Target2.86 (4.15%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-1.75%

PT rev (3m)-16.42%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-20%

EPS NY rev (3m)-25%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-1.81%

Revenue NY rev (3m)-2.56%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.29
P/FCF	17.62
P/OCF	2.14
P/B	0.27
P/tB	0.28
EV/EBITDA	3.04

EPS(TTM)-1.38

EYN/A

EPS(NY)-0.2

Fwd EYN/A

FCF(TTM)0.16

FCFY5.68%

OCF(TTM)1.29

OCFY46.82%

SpS9.62

BVpS10.29

TBVpS9.89

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-8.77%
ROE	-13.28%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	15.49%
FCFM	1.62%

ROA(3y)-7.13%

ROA(5y)-4.46%

ROE(3y)-11.69%

ROE(5y)-7.3%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y8.23%

GM growth 5Y10.12%

F-Score6

Asset Turnover0.62

Health

		Industry Rank	Sector Rank
Debt/Equity	0.06
Debt/FCF	4.63
Debt/EBITDA	0.93
Cap/Depr	140.63%
Cap/Sales	11.75%
Interest Coverage	N/A
Cash Conversion	179.94%
Profit Quality	N/A
Current Ratio	2.53
Quick Ratio	0.93
Altman-Z	1.97

F-Score6

WACC7.43%

ROIC/WACCN/A

Cap/Depr(3y)120.54%

Cap/Depr(5y)120.13%

Cap/Sales(3y)13.95%

Cap/Sales(5y)12.23%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)31.38%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%62.14%

EPS Next Y58.04%

EPS Next 2Y42.16%

EPS Next 3Y35.66%

EPS Next 5Y26.56%

Revenue 1Y (TTM)-9.79%

Revenue growth 3Y0.98%

Revenue growth 5Y0.07%

Sales Q2Q%-10.01%

Revenue Next Year-0.96%

Revenue Next 2Y-2.87%

Revenue Next 3Y-0.73%

Revenue Next 5Y0.07%

EBIT growth 1Y-293.18%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year255.22%

EBIT Next 3Y69.8%

EBIT Next 5Y39.61%

FCF growth 1Y111.67%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y2309.8%

OCF growth 3Y19.68%

OCF growth 5Y28.63%

EUROAPI SASU (EAPI.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens